Nassim SALEM

Mr. Nassim SALEM

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Philippe RochigneuxPhilippe Rochigneux
Philippe Rochigneux
ALAaron Lisberg
Aaron Lisberg
AGAlejandro Garcia
Alejandro Garcia
SGSamuel Granjeaud
Samuel Granjeaud
AMAnne Madroszyk
Anne Madroszyk
EGEdward B. Garon
Edward B. Garon
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers of their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors of pembrolizumab efficacy in patients with advanced NSCLC. Experimental Design: We used high-dimensional mass cytometry (CyTOF) in baseline blood samples of patients with advanced NSCLC treated with pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and confirmed by manual gating followed by principal component analysis (between-group analysis). Results: We analyzed 27 patients from the seminal KEYNOTE-001 study (median follow-up of 60.6 months). We demonstrate that blood baseline frequencies of classical monocytes, natural killer (NK) cells, and ICOS+ CD4+ T cells are significantly associated with improved objective response rates, progression-free survival, and overall survival (OS). In addition, we report that a baseline immune peripheral score combining these three populations strongly predicts pembrolizumab efficacy (OS: HR = 0.25; 95% confidence interval = 0.12–0.51; P < 0.0001). Conclusions: As this immune monitoring is easy in routine practice, we anticipate our findings may improve prediction of ICI benefit in patients with advanced NSCLC.

13 January 2023 in Analytica Chimica Acta
Verified
Journal Article
Closed access
BCBenoît Chovelon
Benoît Chovelon
EPEric Peyrin
Eric Peyrin
MRMaïlys RAGOT
Maïlys RAGOT
NSNassim SALEM
Nassim SALEM
TNTruong Giang Nguyen
Truong Giang Nguyen
CRCorinne Ravelet
Corinne Ravelet

22 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
AFAnne-Charlotte Le Floch
Anne-Charlotte Le Floch
MRMarie-Sarah Rouvière
Marie-Sarah Rouvière
NSNassim SALEM
Nassim SALEM
AAAmira Ben Amara
Amira Ben Amara
FOFlorence Orlanducci
Florence Orlanducci
DODaniel Olive
Daniel Olive
The success of immunotherapy has highlighted the critical role of the immune microenvironment in acute lymphoblastic leukemia (ALL); however, the immune landscape in ALL remains incompletely understood and most studies have focused on conventional T cells or NK cells. This study investigated the prognostic impact of circulating γδ T-cell alterations using high-dimensional analysis in a cohort of newly diagnosed adult ALL patients (10 B-ALL; 9 Philadelphia+ ALL; 9 T-ALL). Our analysis revealed common alterations in CD8+ T cells and γδ T cells of relapsed patients, including accumulation of early stage differentiation and increased expression of BTLA and CD73. We demonstrated that the circulating γδ T-cell signature was the most discriminating between relapsed and disease-free groups. In addition, Vδ2 T-cell alterations strongly discriminated patients by relapse status. Taken together, these data highlight the role of ɣδ T cells in adult ALL patients, among whom Vδ2 T cells may be a pivotal contributor to T-cell immunity in ALL. Our findings provide a strong rationale for further monitoring and potentiating Vδ2 T cells in ALL, including in the autologous setting.

1 April 2023
Verified
Other
Open access
Philippe RochigneuxPhilippe Rochigneux
Philippe Rochigneux
ALAaron Lisberg
Aaron Lisberg
AGAlejandro Garcia
Alejandro Garcia
SGSamuel Granjeaud
Samuel Granjeaud
AMAnne Madroszyk
Anne Madroszyk
EGEdward B. Garon
Edward B. Garon
Purpose:Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers of their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors of pembrolizumab efficacy in patients with advanced NSCLC. Experimental Design:We used high-dimensional mass cytometry (CyTOF) in baseline blood samples of patients with advanced NSCLC treated with pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and confirmed by manual gating followed by principal component analysis (between-group analysis).Results:We analyzed 27 patients from the seminal KEYNOTE-001 study (median follow-up of 60.6 months). We demonstrate that blood baseline frequencies of classical monocytes, natural killer (NK) cells, and ICOS+ CD4+ T cells are significantly associated with improved objective response rates, progression-free survival, and overall survival (OS). In addition, we report that a baseline immune peripheral score combining these three populations strongly predicts pembrolizumab efficacy (OS: HR = 0.25; 95% confidence interval = 0.12–0.51; P < 0.0001).Conclusions:As this immune monitoring is easy in routine practice, we anticipate our findings may improve prediction of ICI benefit in patients with advanced NSCLC.

1 April 2023
Verified
Other
Open access
Philippe RochigneuxPhilippe Rochigneux
Philippe Rochigneux
ALAaron Lisberg
Aaron Lisberg
AGAlejandro Garcia
Alejandro Garcia
SGSamuel Granjeaud
Samuel Granjeaud
AMAnne Madroszyk
Anne Madroszyk
EGEdward B. Garon
Edward B. Garon
Purpose:Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers of their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors of pembrolizumab efficacy in patients with advanced NSCLC. Experimental Design:We used high-dimensional mass cytometry (CyTOF) in baseline blood samples of patients with advanced NSCLC treated with pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and confirmed by manual gating followed by principal component analysis (between-group analysis).Results:We analyzed 27 patients from the seminal KEYNOTE-001 study (median follow-up of 60.6 months). We demonstrate that blood baseline frequencies of classical monocytes, natural killer (NK) cells, and ICOS+ CD4+ T cells are significantly associated with improved objective response rates, progression-free survival, and overall survival (OS). In addition, we report that a baseline immune peripheral score combining these three populations strongly predicts pembrolizumab efficacy (OS: HR = 0.25; 95% confidence interval = 0.12–0.51; P < 0.0001).Conclusions:As this immune monitoring is easy in routine practice, we anticipate our findings may improve prediction of ICI benefit in patients with advanced NSCLC.

11 March 2016 in European Urology Supplements
Verified
Journal Article
Closed access
NBN. Branger
N. Branger
TMT. Maubon
T. Maubon
MTM. Traumann
M. Traumann
JTJ. Thomassin
J. Thomassin
MPM. Pacienca
M. Pacienca
JWJ. Walz
J. Walz